title: [Oxaliplatin: perspectives and future developments].
authors.forename: M
authors.initials: M
authors.lastname: Marty
authors.forename: P H
authors.initials: PH
authors.lastname: Cottu
authors.forename: F
authors.initials: F
authors.lastname: Lerebours
authors.forename: N
authors.initials: N
authors.lastname: Bedairia
authors.forename: H
authors.initials: H
authors.lastname: Hocini
authors.forename: M
authors.initials: M
authors.lastname: Espié
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000188:drug therapy; D015179:Colorectal Neoplasms / Q000188:drug therapy; D004357:Drug Synergism; D004791:Enzyme Inhibitors / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D009944:Organoplatinum Compounds / Q000627:therapeutic use*; D000077150:Oxaliplatin; D010190:Pancreatic Neoplasms / Q000188:drug therapy; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors
chemical_list: D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D013940:Thymidylate Synthase